» Articles » PMID: 37093836

Mycobacterium Ulcerans Culture Results According to Duration of Prior Antibiotic Treatment: A Cohort Study

Overview
Journal PLoS One
Date 2023 Apr 24
PMID 37093836
Authors
Affiliations
Soon will be listed here.
Abstract

Mycobacterium ulcerans disease is a necrotising disease of the skin and subcutaneous tissue and is effectively treated with eight-weeks antibiotic therapy. Significant toxicities, however, are experienced under this prolonged regimen. Here, we investigated the length of antibiotic duration required to achieve negative cultures of M. ulcerans disease lesions and evaluated the influence of patient characteristics on this outcome. M. ulcerans cases from an observational cohort that underwent antibiotic treatment prior to surgery and had post-excision culture assessment at Barwon Health, Victoria, from May 25 1998 to June 30 2019, were included. Antibiotic duration before surgery was grouped as <2 weeks, ≥2-<4 weeks, ≥4-<6 weeks, ≥6-<8 weeks, ≥8-<10 weeks and ≥10-20 weeks. Cox regression analyses were performed to assess the association between variables and culture positive results. Ninety-two patients fitted the inclusion criteria. The median age was 60 years (IQR 28-74.5) and 51 (55.4%) were male. Rifampicin-based regimens were predominantly used in combination with clarithromycin (47.8%) and ciprofloxacin (46.7%), and the median duration of antibiotic treatment before surgery was 23 days (IQR, 8.0-45.5). There were no culture positive results after 19 days of antibiotic treatment and there was a significant association between antibiotic duration before surgery and a culture positive outcome (p<0.001). The World Health Organisation category of the lesion and the antibiotic regimen used had no association with the culture outcome. Antibiotics appear to be effective at achieving negative cultures of M. ulcerans disease lesions in less than the currently recommended eight-week duration.

Citing Articles

Improved protocols for isolation of Mycobacterium ulcerans from clinical samples.

Agbavor B, Arthur R, Agbanyo A, Ahiatrogah D, Akenten C, Adu-Asiamah C BMC Microbiol. 2025; 25(1):118.

PMID: 40045245 PMC: 11881482. DOI: 10.1186/s12866-025-03835-6.


A human model of Buruli ulcer: Provisional protocol for a controlled human infection study.

Muhi S, Marshall J, OBrien D, Johnson P, Ross G, Ramakrishnan A Wellcome Open Res. 2024; 9:488.

PMID: 39386965 PMC: 11462124. DOI: 10.12688/wellcomeopenres.22719.1.

References
1.
OBrien D, Murrie A, Meggyesy P, Priestley J, Rajcoomar A, Athan E . Spontaneous healing of Mycobacterium ulcerans disease in Australian patients. PLoS Negl Trop Dis. 2019; 13(2):e0007178. PMC: 6396929. DOI: 10.1371/journal.pntd.0007178. View

2.
OBrien D, Friedman N, Cowan R, Walton A, Athan E . Six vs Eight Weeks of Antibiotics for Small Mycobacterium ulcerans Lesions in Australian Patients. Clin Infect Dis. 2019; 70(9):1993-1997. DOI: 10.1093/cid/ciz532. View

3.
Gordon C, Buntine J, Hayman J, Lavender C, Fyfe J, Hosking P . All-oral antibiotic treatment for buruli ulcer: a report of four patients. PLoS Negl Trop Dis. 2010; 4(11):e770. PMC: 2994921. DOI: 10.1371/journal.pntd.0000770. View

4.
OBrien D, Jenkin G, Buntine J, Steffen C, McDonald A, Horne S . Treatment and prevention of Mycobacterium ulcerans infection (Buruli ulcer) in Australia: guideline update. Med J Aust. 2014; 200(5):267-70. DOI: 10.5694/mja13.11331. View

5.
Ji B, Chauffour A, Robert J, Lefrancois S, Jarlier V . Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother. 2007; 51(10):3737-9. PMC: 2043285. DOI: 10.1128/AAC.00730-07. View